TAILIEUCHUNG - CDC’s Vision for Public Health Surveillance in the 21st Century

Health care reform is a total business issue that inl uences benei ts, the overall reward deal, workforce planning, administration and i nances. This is an important time for employers to revisit their total rewards philosophy and strategy, and understand the kinds of changes that may be necessary to meet their business and growth goals, shifting talent requirements and the i nancial pressures they continue to face. Our survey results indicate that 30% of companies are taking steps to examine their health care benei ts, employee subsidies and out-of-pocket costs (including health management, and worksite and prevention programs) in a. | Centers for Disease Control and Prevention MMWR Morbidity and Mortality Weekly Report July 27 2012 Supplement I Vol. 61 CDCs Vision for Public Health Surveillance in the 21st Century . Department of Health and Human Services Centers for Disease Control and Prevention Supplement CONTENTS Public Health Surveillance in the United States Evolution and Lexicon Definitions and Conceptual Framework for Public Health Global Health The Role of Public Health Informatics in Enhancing Public Health Public Health Surveillance Workforce of the Public Health Surveillance Data Legal Policy Ethical Regulatory and Practical Analytical Challenges for Emerging Public Health Surveillance . 35 The MMWR series of publications is published by the Office of Surveillance Epidemiology and Laboratory Services Centers for Disease Control and Prevention CDC . Department of Health and Human Services Atlanta GA 30333. Suggested Citation Centers for Disease Control and Prevention. Title . MMWR 2012 61 Suppl July 27 2012 inclusive page numbers . Centers for Disease Control and Prevention Thomas R. Frieden MD MPH Director Harold W. Jaffe MD MA Associate Director for Science James W. Stephens PhD Director Office of Science Quality Stephen B. Thacker MD MSc Deputy Director for Surveillance Epidemiology and Laboratory Services Stephanie Zaza MD MPH Director Epidemiology and Analysis Program Office MMWR Editorial and Production Staff Ronald L. Moolenaar MD MPH Editor MMWR Series Christine G. Casey MD Deputy Editor MMWR Series Teresa F. Rutledge Managing Editor MMWR Series David C. Johnson Lead Technical Writer-Editor Project Editor Lisa M. Lee PhD Stephen B. Thacker MD Pamela A. Meyer PhD Guest Editors Martha F. Boyd Lead Visual Information Specialist Maureen A. Leahy Julia C. Martinroe Stephen R. Spriggs Terraye M. Starr Visual Information Specialists Quang M. Doan MBA Phyllis H. King Information .

• Y học thường thức
• Systemic Therapy
• Advanced Pancreatic Carcinoma
• Immunotherapy
• Overview
• Bacterial Immunotherapy
• Antitumoral Potential
• Hepatocellular carcinoma
• Systemic therapy for hepatocellular carcinoma
• Adjuvant regimens for HCC
• Sorafenib was first approved
• Prolong survival of the patients
• Barcelona Classification
• Summary of doctoral thesis
• Immune disorders and results of pulse methylprednisolone therapy
• Severe systemic lupus erythematosus
• Target organ damage and activity level
• Pulsed methylprednisolone therapy combined
• BMC Cancer
• Adjuvant temozolomide
• Multimodality therapy approaches
• Systemic treatment
• Radiation therapy
• BMC Pulmonary medicine
• Systemic glucocorticoid therapy
• Plasma metabolome
• Systemic glucocorticoid
• Acute exacerbation
• Chronic obstructive pulmonary disease
• Phase II trial
• Selective internal radiation therapy
• Systemic chemotherapy
• Liver predominant metastases
• Pancreatic adenocarcinoma
• Bladder cancer
• Radical cystectomy
• Perioperative chemotherapy
• Perioperative targeted therapy
• Immune therapy
• Gene therapy
• Human HCC cells
• Modified molecule
• Systemic HCC therapy
• Ewing sarcoma
• Complete remission
• Metastatic disease
• Distant metastasis
• Biliary cancer
• Younger patients
• Prospective trials
• Corticosteroids and steroid therapy
• Steroid therapy
• The manager
• Chronic subdural hematoma
• Clinical considerations
• Systemic autoimmune diseases
• Risk factors
• Intrauterine therapy
• Hormonal therapy
• Metritis in cattle
• Competitive mortality
• Non tumoral death
• Head and neck cancer
• Breast cancer
• Neoadjuvant systemic therapy
• Nodal staging
• Chest CT
• BMC Musculoskeletal Disorders
• Rheumatoid arthritis
• Systemic lupus erythematosus
• Autoimmune disorders
• Osteoporotic fractures
• BMC Anesthesiology
• Local anesthetic systemic toxicity
• Lipid rescue therapy
• Intravenous lipid emulsions
• Several international anesthesia organizations
• Carbon monoxide
• Life threatening
• Systemic hyperbaric oxygen
• CO detoxification
• Severely intoxicated patients
• Prognostic models
• Review and critical appraisal
• Advanced hepatocellular carcinoma
• Liver cancer
• Randomized controlled trial
• Systemic anticancer therapy
• Targeted therapy
• Non standard
• Survival outcomes
• Slow growing neoplasm
• Radiological response
• Pancreatic cancer
• Advanced disease
• Second line therapy Progression free survival
• Overall survival
• Biliary tract cancer
• Combination therapy
• Prior systemic therapies
• Prospective randomized
• Neoadjuvant treatment
• Endocrine therapy
• Treatment response
• Post treatment surgical management